|

Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine Tumors

RECRUITINGPhase 1/2Sponsored by Peking Union Medical College Hospital
Actively Recruiting
PhasePhase 1/2
SponsorPeking Union Medical College Hospital
Started2023-03-23
Est. completion2025-03-27
Eligibility
Age18 Years – 80 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06056362

Summary

This prospective, single-center, double-blinded study investigates the biodistribution, dosimetry, safety, and diagnostic ability of Al18F-NOTA-LM3 in patients with well-differentiated neuroendocrine tumors. And compares the diagnostic ability of Al18F-NOTA-LM3 with 68Ga-DOTATATE PET/CT and 68Ga-NODAGA-LM3 PET/CT. Clinical management will also be compared using different imaging modalities.

Eligibility

Age: 18 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria:

* Patients aged 18 to 80 years.
* Histologically proven, well-differentiated, NETs (G1 or G2).
* No long-acting somatostatin analog treatment within 4 weeks.
* No PRRT treatment within 8 weeks.

Exclusion Criteria:

* Combined with other types of tumors.
* Severe liver or renal dysfunction (ALT/AST≥5 ULN, GFR\<30ml/min).
* Active infection.
* Pregnant or breast-feeding women.
* Inability to perform PET/CT scans.

Conditions2

CancerNeuroendocrine Tumors

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.